Table 2.
HIV-1–specific peptide pools used in ELISpot assays of peripheral blood mononuclear cells from study volunteers who received HIV vaccine.
| Peptide pool | Protein | Peptide number | Clade | Source |
|---|---|---|---|---|
| Gag Ia | p17 | 1–26 | B | Thermo Scientific |
| Gag IIa | p24 | 27–71 | A | Thermo Scientific |
| Env Ia | gp120, including V1 and V2 | 1–50 | A/B | Thermo Scientific |
| Env IIa | gp120, including V3-V5 | 51–100 | A | Thermo Scientific |
| Env IIIa | gp41 | 101–169 | B | Thermo Scientific |
| RT I | pol | 1–55 | B | NIBSC |
| RT II | pol | 56–110 | B | NIBSC |
| Gag WRb | p6, p7, p17, p24 | 1–160 | A | WRAIR |
NOTE. MVA, modified vaccinia virus Ankara; NIBSC, National Institute for Biological Standards and Control; WRAIR, Walter Reed Army Institute of Research.
a
DNA vaccine clade A–specific and clade B–specific peptides. All peptides were 15-mers with 10-aa overlap.
b
The peptides included in the Gag WR pool were specific for the HIV inserts in MVA and were 15-mers with an 11-aa overlap. This peptide pool was included in assays of samples obtained at the time of HIV-1 MVA boosting vaccination and 2 weeks after HIV-1 MVA boosting vaccination.